-
31.
公开(公告)号:CA2245587C
公开(公告)日:2008-12-30
申请号:CA2245587
申请日:1997-02-12
Applicant: ABBOTT LAB
Inventor: BOYD STEVEN A , WINN MARTIN , HUTCHINS CHARLES W , HENRY KENNETH J , LIU GANG , SZCZEPANKIEWICZ BRUCE G , WITTENBERGER STEVEN J , TASKER ANDREW S , KING STEVEN A , VON GELDERN THOMAS W , KESTER JEFFREY A , JAE HWAN-SOO , SORENSEN BRYAN K
IPC: C07D405/04 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/495 , A61K31/506 , A61K31/675 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P25/06 , A61P43/00 , C07D207/16 , C07D211/60 , C07D401/04 , C07D403/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07D453/02 , C07D471/04 , C07D491/04 , C07F9/572
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
-
公开(公告)号:AU2005201160A1
公开(公告)日:2005-04-14
申请号:AU2005201160
申请日:2005-03-17
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , GELDERN THOMAS W VON , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A
IPC: C07D405/00
-
33.
公开(公告)号:NZ514171A
公开(公告)日:2003-10-31
申请号:NZ51417197
申请日:1997-02-12
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN SOO , TASKER ANDREW S , VON GELDERN THOMAS V , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , ENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A
Abstract: Compounds a) (2R, 3R, 4S)-2-(3-Fluoro-4methoxyphenyl)-4-(1.3- benzodioxol-5-yl)-1-(2-(N-propyl-N- pentanesulfonylamino)ethyl)-pyrrolidine-3-carboxylic acid b) trans, trans-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3- benzodioxol-5-yl)-1-(N,N-dibutylaminocarbonylmethyl)- pyyrolidine-3-carboxylic acid c) trans, trans-2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5- yl)-1-[(N-butyl-N-(4- dimethylaminobutyl)amino)carbonylmethyl]-pyyrolidine-3- carboxylic acid The uses of the compounds may include antagonsing endothelin in a mammal, treating - hypertension, congestive heart failure, restenosis following arterial injury, cerebral ischemia, myocardial ischemia, atherosclerosis, angina, cerebral vasospasm, a LPL-related lipoprotein disorder, Raynaud's disease, nociception and cancer.
-
公开(公告)号:DK0776324T3
公开(公告)日:2002-10-07
申请号:DK95928323
申请日:1995-08-04
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , VONGELDERN THOMAS W , KESTER JEFFREY A , SORENSEN BRYAN K
IPC: A61K31/40 , A61K31/402 , A61K31/4025 , A61K31/403 , A61K31/41 , A61K31/415 , A61K31/422 , A61K31/435 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/454 , A61K31/47 , A61K31/505 , A61K31/506 , A61K31/535 , A61K31/5377 , A61P9/00 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D207/14 , C07D207/16 , C07D401/04 , C07D403/04 , C07D405/04 , C07D405/10 , C07D405/14 , C07D413/04 , C07D419/04 , C07D471/04 , C07F9/572 , C07F9/59
Abstract: Processes for preparing endothelin antagonists of formula (I) and pharmaceutically acceptable salts thereof and processes for preparing intermediates thereof.
-
公开(公告)号:CO5190718A1
公开(公告)日:2002-08-29
申请号:CO98043616
申请日:1998-07-31
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , BOYU STEVEN A , HUTCHINS CHARLES W , HWAN-SOO JEE , TASKER ANDREW S , GELDERN THOMAS W VON , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEW BRUCE G , HENRY KENNETH J , GANG LIU , WITTENBERGER STEVEN J , KING STEVEN A
IPC: A61K31/16 , A61K31/40 , A61K31/435
Abstract: Compuesto de fórmula: en dondeZ es -C(R18)(R19)- ó -C(O)- en donde R18 y R19 son independientemente seleccionados entre hidrógeno y alquil de cadena corta;n es 0 ó 1;R es -(CH2)m-W en donde m es un entero entre 0 - 6 y W es(a) -C(O)2-G en donde G es hidrógeno ó un grupo protector de carboxi,(b) -PO3H2,(c) -P(O)(OH)E en donde E es hidrógeno, alquil de cadena corta ó arilalquil,(d) -CN,(e) -C(O)NHR17 en donde R17 es alquil de cadena corta,(f) alquilaminocarbonil,(g) dialquilaminocarbonil,(h) tetrazolil,(i) hidroxi,(j) alcoxi,(k) sulfonamido,(I) -C(O)NHS(O)2R16 en donde R16 es alquil de cadena corta, haloalquil, aril ó dialquilamino,(m) -S(O)2NHC(O)R16 en donde R16 corresponde a lo previamente definido, - 2 - R1 y R2 se seleccionan independientemente entre hidrógeno, alquil de cadena corta, alquenil, alquinil, alcoxialquil, alcoxicarbonilalquil, hidroxialquil, haloalquil, haloalcoxialquil, alcoxialcoxialquil, tioalcoxialcoxialquil, cicloalquil, cicloalquilalquil, aminocarbonilalquil, alquilaminocarbonil-alquil, dialquilaminocarbonilalquil, aminocarbonilalquenil, alquilaminocarbonilalquenil, dialquilamino-carbonilalquenil, hidroxialquenil, aril, arilalquil,ariloxialquil, arilalcoxialquil, (N-alcanoil-N-alquil)aminoalquil, alquilsulfonilamidoalquil, heterocíclico, (heterocíclico)alquil y (Raa)(Rbb)N-Rcc- en donde Raa es aril ó arilalquil, Rbb es hidrógeno ó alcanoil y Rcc es alquilen, con la condición de que uno ó ambos sustituyentes R1 y R2 sean diferentes a hidrógeno;R3 es(a) R4-C(O)-R5-, R4-R5a-, R4-C(O)-R5-N(R6)-, R6-S(O)2-R7- Ó R26-S(O)2-R27-en donde R5 es (i) un enlace covalente, (ii) alquilen, (iii) alquenilen, (iv) -N(R20)-R8- ó -R8a-N(R20)-R8-en donde R8 y R8a se seleccionan independientemente del grupo conformado por alquilen y alquenilen y R20 es hidrógeno, alquil de cadena corta, alquenil, haloalquil, alcoxialquil, haloalcoxialquil, cicloalquil ó cicloalquilalquil ó (v) -O-R9- ó -R9a-O-R9- en donde R9 y R9a se seleccionanindependientemente entre alquilenos;R5a es (i) alquilen ó (ii) alquenilen;R7 es (i) un enlace covalente, (ii) alquilen, (iii) alquenilen ó(iv) -N(R21)-R10- ó -R10a-N(R21)-R10-en donde R10 y R10a se seleccionan independientemente del grupo conformado por alquilen y alquenilen yR21 es hidrógeno, alquil de cadena corta, alquenil, haloalquil, alcoxialquil, haloalcoxialquil, aril ó arilalquil;R4 y R6 son independientemente seleccionados de un grupo conformado por:(i) (R11)(R12)N- en donde R11 y R12 se seleccionan independientemente del grupo conformado por(1) hidrógeno,(2) alquil de cadena corta,(3) haloalquil,(4) alcoxialquil,(5) haloalcoxialquil,(6) alquenil,(7) alquinil,(8) cicloalquil,(9) cicloalquilalquil,(10) aril,(11) heterocíclico,(12) arilalquil,(13) (heterocíclico)alquil,(14) hidroxialquil,(15) alcoxi,(16) aminoalquil,{17) trialquilaminoalquil,(18) alquilaminoalquil,(19) dialquilaminoalquil, y(20) carboxialquil,- 3 -(ii) alquil de cadena corta,(iii) alquenil,(iv) alquinil,(v) cicloalquil,(vi) cicloalquilalquil,(vii) aril,(viii) arilalquil,(ix) heterocíclico,(x) (heterocíclico)alquil,(xi) alcoxialquil,(xii) hidroxialquil,(xiii) haloalquil,(xiv) haloalquenil,(xv) haloalcoxialquil,(xvi) haloalcoxi,(xvii) alcoxihaloalquil,(xviii) alquilaminoalquil,(xix) dialquilaminoalquil(xx) alcoxi, y (xxi)en donde z va de 0 a 5 y R7a es alquilen;R26 es (i) alquil de cadena corta, (ii) haloalquil, (iii) alquenil, (iv) alquinil, (v) cicloalquil, (vi) cicloalquilalquil, (vii) aril, (viii) arilalquil, (ix) heterocíclico (x) (heterocíclico)alquil, (xi) (aIcoxialquil, ó (xii) haloalquil sustituido con alcoxi, yR27 es alquilen o alquenilen;(b) R22-O-C(O)-R23;- en donde R22 es un grupo protector de carboxi ó un heterocíclico y R23 es (i) un enlace covalente, (ii) alquilen, (iii) alquenilen ó (iv) -N(R24)-R25- en donde R25 es alquilen y R24 es hidrógeno ó alquil de cadena corta,(c) alquil de cadena corta,(d) alquenil,(e) alquinil,(f) cicloalquil,(9) cicloalquilalquil,(h) aril,(i) arilalquil,(j) ariloxialquil,(k) heterocíclico,(I) (heterocíclico)alquil,(m) alcoxialquil,(n) alcoxialcoxialquil, ú(o) R13-C(O)-CH(R14)-en donde R13 es amino, alquilamino ó dialquilamino, y R14 es aril, R15-C(O)- en donde R15 es amino, alquilamino ó dialquilamino;ó una sal farmacéuticamente aceptable de éste.
-
36.
公开(公告)号:AU2984101A
公开(公告)日:2002-08-08
申请号:AU2984101
申请日:2001-03-23
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , KING STEVEN A , WITTENBERGER STEVEN J , LIU GANG , HENRY KENNETH J JR , SZCZEPANKIEWICZ BRUCE G , SORENSEN BRYAN K , KESTER JEFFREY A , GELDERN THOMAS W VON , TASKER ANDREW , JAE HWAN-SOO , HUTCHINS CHARLES W , BOYD STEVEN A
IPC: A61K31/40 , C07D207/16 , C07D401/04 , C07D405/04 , C07D405/14 , C07F9/572 , C07F9/59
-
公开(公告)号:HU0003484A2
公开(公告)日:2002-01-28
申请号:HU0003484
申请日:1998-07-27
Applicant: ABBOTT LAB
Inventor: BOYD STEVEN A , HENRY KENNETH J , HUTCHINS CHARLES W , JAE HWAN-SOO , KESTER JEFFREY A , KING STEVEN A , LIU GANG , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , TASKER ANDREW S , WINN MARTIN , WITTENBERGER STEVEN J , VON GELDERN THOMAS W
IPC: C07D491/048 , A61K31/40 , A61K31/41 , A61K31/423 , A61K31/435 , A61K31/4355 , A61K31/495 , A61K31/506 , A61K31/535 , A61K31/55 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/08 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/08 , A61P13/12 , A61P21/00 , A61P21/04 , A61P25/06 , A61P35/00 , A61P43/00 , C07D207/16 , C07D207/26 , C07D207/27 , C07D403/04 , C07D405/00 , C07D405/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D491/056
-
公开(公告)号:TR200000993T2
公开(公告)日:2000-12-21
申请号:TR200000993
申请日:1998-07-27
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , GELDERN THOMAS W VON , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A
IPC: C07D491/048 , A61K31/40 , A61K31/41 , A61K31/423 , A61K31/435 , A61K31/4355 , A61K31/495 , A61K31/506 , A61K31/535 , A61K31/55 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/08 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/08 , A61P13/12 , A61P21/00 , A61P21/04 , A61P25/06 , A61P35/00 , A61P43/00 , C07D207/16 , C07D207/26 , C07D207/27 , C07D403/04 , C07D405/00 , C07D405/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D491/056
-
39.
公开(公告)号:CZ253798A3
公开(公告)日:1999-07-14
申请号:CZ253798
申请日:1997-02-12
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , VON GELDERN THOMAS W , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J JR , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A
IPC: A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/495 , A61K31/506 , A61K31/675 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P25/06 , A61P43/00 , C07D207/16 , C07D211/60 , C07D401/04 , C07D403/04 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07D453/02 , C07D471/04 , C07D491/04 , C07F9/572 , C07D413/04 , A61K31/445
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
-
40.
公开(公告)号:CA2634973A1
公开(公告)日:1997-08-21
申请号:CA2634973
申请日:1997-02-12
Applicant: ABBOTT LAB
Inventor: SORENSEN BRYAN K , KESTER JEFFREY A , VON GELDERN THOMAS W , TASKER ANDREW S , JAE HWAN-SOO , BOYD STEVEN A , HUTCHINS CHARLES W , WINN MARTIN , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J JR , KING STEVEN A , WITTENBERGER STEVEN J , LIU GANG
IPC: A61K31/4025 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/495 , A61K31/506 , A61K31/675 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P25/06 , A61P29/00 , A61P35/00 , A61P43/00 , C07D207/16 , C07D211/60 , C07D401/04 , C07D403/04 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07D453/02 , C07D471/04 , C07D491/04 , C07F9/572
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
-
-
-
-
-
-
-
-
-